SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently a focal point for investors as intense options activity and bullish institutional positioning emerge ahead of its earnings release. The community remains sharply divided between those betting on an explosive recovery fueled by massive AI data center demand and those wary of short-seller reports and recent supply chain volatility.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning is experiencing extreme volatility as investors recalibrate expectations following a revenue guidance miss, overshadowing strong AI-driven optical demand and major data center partnerships. The community remains deeply divided, with some traders panicking over technical breakdowns and potential downside, while others view the pullback as a long-term buying opportunity in critical AI infrastructure.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is experiencing intense volatility and a significant share price decline following the release of FDA briefing documents that challenge the statistical integrity of its HOPE-3 clinical trial. The community is sharply divided, with bulls pointing to the potential for a positive AdCom vote and citing discrepancies in the FDA's analysis as a tactical error, while bears and skeptics argue that the company engaged in inappropriate post-hoc data manipulation.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is surging as investors react to news that the FDA has agreed to a path for resubmitting the BLA for RP1, sparking intense community debate over whether this third attempt will bypass previous efficacy concerns. While bulls are celebrating a potential regulatory reversal and short squeeze, skeptics warn that the stock remains a high-risk binary play, highlighting lingering questions about trial design and the company's financial runway.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant investor skepticism ahead of its earnings report, with community members expressing frustration over consistent late-day sell-offs and perceived price manipulation. Much of the discourse centers on intense debate regarding whether massive AI infrastructure and capital expenditure plans will drive future growth or lead to further margin compression.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is experiencing intense volatility and a significant correction, driven by a combination of broader semiconductor sector weakness, fears regarding Chinese competition, and a massive unwinding of leveraged positions. While many investors are debating if the stock has reached a bottom, the community is sharply divided between those viewing the decline as a major buying opportunity ahead of upcoming earnings and those warning of further downside due to excessive previous valuation gains.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Singapore.

Seagate Technology Holdings Plc

Seagate Technology is trending as investors aggressively reposition around storage and memory stocks ahead of the company's upcoming earnings report. The stock's volatile price action has sparked intense debate, with the community split between those betting on long-term AI-driven infrastructure demand and those fearing a cyclical peak or potential short-term pullback.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is capturing significant investor attention as the stock maintains a strong bullish trend driven by impressive Q1 membership growth and improved medical loss ratios. The community remains focused on whether the company can sustain this momentum into the 30-40 dollar range, with many investors debating the durability of its growth story versus potential short-term pullbacks.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is currently in the spotlight as investors evaluate a robust quarterly performance characterized by double-digit revenue growth and a new multi-billion dollar share buyback program. While market sentiment remains focused on the company's resilient transaction volume and strategic expansion into AI-driven commerce, traders are actively debating the stock's valuation versus long-term growth prospects as it navigates a broader rotation out of tech momentum.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford Motor Co. is trending as investors scrutinize the company's Q2 earnings results and guidance, while community discussions focus on its expansion into energy storage systems for AI data centers and strategic partnerships to secure memory chip supply chains. Traders are actively debating the stock's future momentum, balancing optimism around new tactical vehicle contracts and potential UEV platform developments against concerns regarding vehicle recalls and fluctuating automotive demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS The FOX TV segment is designed to create an environment where Big Pharma boards face massive internal pressure. No shareholder will question why a giant like JNJ or Merck paid an elite premium price; they will be demanding to know why their board didn&#39;t move faster to lock down a plug-and-play monopoly asset before a competitor did.

10xorbust

Zschopower

Rick Glowaki

Fausto Rossi

Paul Nealy

Gopirates1869

Allan Kristensen

Peggy Murphy

THE KINGS REVIEWS

Johan Sundell

상후니

Ghost

Alex Vazquez

Chessdoc

Jon brand

Nick

Timetravelerdos

Jimmy2020

Longnstrongdong

J Mattila

mrittika1971

Buffet87

$SLS They aren’t leading with a micro-cap ticker on national television. The prime-time sequencing is completely intentional. 

The Hook: Open with the network&#39;s massive $185T economic windfall narrative to grab Wall Street&#39;s attention.

The Scale: Narrow it down to the 30.7 million Americans projected to die from cancer between 2030 - 2064, trapped in the high-risk, post-remission observation gap.

The Solution: Drop the mic with the GPS platform—explaining how a universal, off-the-shelf biologic uses a CD4 software update to maintain continuous immune surveillance and keep aggressive cancers permanently dormant.

StockTwits for iOS

SELLAS Life Sciences Group Inc

Duncan Teo

 The FOX TV segment is designed to create an environment where Big Pharma boards face massive internal pressure. No shareholder will question why a giant like JNJ or Merck paid an elite premium price; they will be demanding to know why their board didn't move faster to lock down a plug-and-play monopoly asset before a competitor did.

@Duncan74 no big pharma company is paying $10 billion plus (or $20 billion or $30 or $40) for
   $SLS without the Regal results being a big success or a clause in the asset purchase agreement that the price is contingent upon those results.

￼But if those Regal results are good the price is off to the races given the desperation of big Pharma and the impending patent Cliff.   $MRK offered $32 billion for development stage Biotech $RVMD to try to get Daraonrasib.

TheOncoTrader

Merck & Co Inc

Revolution Medicines Inc

 no big pharma company is paying $10 billion plus (or $20 billion or $30 or $40) for
   

 without the Regal results being a big success or a clause in the asset purchase agreement that the price is contingent upon those results.

￼But if those Regal results are good the price is off to the races given the desperation of big Pharma and the impending patent Cliff.   

 offered $32 billion for development stage Biotech 

@10xorbust Big Pharma companies are highly accustomed to bidding on contingent terms. It is entirely possible for players like JNJ (chasing its massive $50B oncology target) or Merck to submit signed, binding offers where the final execution and premium are legally triggered by a successful statistical verdict from the CRO. If multiple suitors have vetted the universal WT1 platform, Stifel can easily narrow the field down to a selected &quot;winner&quot; whose finalized contract sits waiting on a desk.

 Big Pharma companies are highly accustomed to bidding on contingent terms. It is entirely possible for players like JNJ (chasing its massive $50B oncology target) or Merck to submit signed, binding offers where the final execution and premium are legally triggered by a successful statistical verdict from the CRO. If multiple suitors have vetted the universal WT1 platform, Stifel can easily narrow the field down to a selected "winner" whose finalized contract sits waiting on a desk.